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allowed to move around the device within 10 cm. radius. After 28 days, mRNA 
from the brain of control, sham and GSM-900 MHz exposed rats were isolated 
and subjected to quantitative Real Time Polymerase Chain Reaction (qRT-PCR) 
array analysis. Gene expression was measured and expressed in fold change as 
described by Bandhyopadhay et.al. (2007). The qRT-PCR was performed by using 
sybr green chemistry on ABI 7900HT platform. The real time quantification of 
amplification was done by measuring change in fluorescence by SDS2.3 software 
and further analyze by RQ manager. RESULTS: Thus the results obtained from 
this study have shown that there is no significant change in expressions of genes 
involved in DNA damage and repair pathways such as chromatin assembly 
(CHAF1A), DNA damage checkpoints (Chk1), DNA synthesis (POLD1), post-
transcriptional processes (RBM4), translation synthesis (POLI) and stress 
signaling (Hsp90) as compared with controls. CONCLUSIONS: Mobile phone’s 
acute exposure (GSM900MHz) does not support for genes expression involved in 
DNA damage and repair pathways.  
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OBJECTIVES: In the context of a regional HTA system in the South West of the 
UK, we assessed the potntial cost utility of Sativex relative to oral anti-spasticity 
agents in MS METHODS: A decision-analytic model was developed to estimate 
cost-effectiveness in a cohort of adults who have moderate to severe spasticity 
due to MS. A three state Markov model was used: in response; response lost; 
death. Transition probabilities were obtained from a systematic review of the 
effectiveness of Sativex. The study cohort was aged 50 years (60% women). Cycle 
length was four weeks and time horizon five years. Costs were assessed from the 
perspective of the health care system. In some cases, treatment with botulinum 
toxin or implantation of a baclofen intrathecal pump may be considered and 
these options were explored in sensitivity analysis. Utility data was obtained 
from one of the trials of Sativex using the EQ5D. Extensive one way, threshold 
and probabilistic approaches were taken in analysis of uncertainty. RESULTS: 
The base case ICER was £49,300 per QALY with a probability of cost effectiveness 
at a willingness to pay of £30,000 per QALY of around 10%. Results were sensitive 
to the amount of Sativex per day – at the minimum dose (4 sprays) the ICER was 
around £25,000 per QALY but at the maximum (12 sprays) was nearly £70,000 per 
QALY. Threshold analysis suggests that for the mean dosage given in RCTs to be 
considered cost effective, a 40% reduction in price is needed. Including a 
proportion of people using more expensive current treatments improved 
expected cost effectiveness. CONCLUSIONS: Sativex is unlikely to be considered 
a cost effective treatment for most people who would meet the licensed 
indication for treatment in the UK at this time.  
 
PND54  
TRENDS IN OFF-LABEL ANTIDEPRESSANT USES FOR INSOMNIA IN MEDICARE 
OUTPATIENT SETTINGS  
Lai L, Nguyen T 
Nova Southeastern University, Ft. Lauderdale, FL, USA  
OBJECTIVES: Antidepressants are one of the pharmacologic agents that have 
been intensively prescribed off-label. The study aimed to investigate trends of 
off-label antidepressant uses for insomnia treatment in Medicare population, 
with emphasis on patient and physician’s socioeconomic characteristics. 
METHODS: This project proposed a secondary data analysis using National 
Ambulatory Medical Care Survey 2002 to 2009. Subjects were derived from US 
outpatient visits in which at least one insomnia drug prescribed to Medicare 
beneficiary. Data trends were graphically plotted and analyzed using weight-
adjusted chi-squared analyses. A weighted logistic regression with SAS PROC 
SURVEYLOGISTICS and ROC curve were conducted to predict the maximum 
likelihood of off-label antidepressant use associated with patient and physician 
characteristics. RESULTS: An estimated of 7.56 billion visits occurred to office 
based physician in the US from 2002 to 2009, in which 1.78 billion visits (23.52%) 
were made by Medicare recipients. There were 82.76 million (4.65%) visits, where 
at least one commonly used insomnia drugs was prescribed. Among these, FDA-
approved benzodiazepines were prescribed at 11 million visits (13.3%), FDA-
approved non-benzodiazepine z-hypnotics were at 35 million visits (31.53%), and 
off label antidepressants were at 40 million visits (48.61%). There was 
significantly increased likelihood of prescribing off-label antidepressants in 
relationship to patient’s year of visit, gender, age, and physician’s specialty and 
ownership (P<0.001). The receiver operational characteristic analysis estimated 
the ROC curve of predictor variables was 0.779. CONCLUSIONS: The study 
revealed high prevalent use of off-label antidepressants for insomnia in 
Medicare population. Our results also showed various socioeconomics disparities 
among physician and patients in use of antidepressant for insomnia. These lead 
to great concern of potential legal risk of medication errors, side effects, and 
adverse drug reactions from the unregulated off-label prescriptions.  
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OBJECTIVES: Treatment of acute pain often includes use of nonsteroidal anti-
inflammatory drugs (NSAIDs). Although effective, they are known to cause 
adverse events (AEs), including gastrointestinal, cardiovascular, and renal 
events. The objective of this review was to assess the temporal relationship 
between NSAID use and risk of gastrointestinal, cardiovascular, and renal  
AEs METHODS: For the systematic review, the PubMed electronic database  
was searched for articles published in English related to the temporal 
relationship between NSAIDs and development of gastrointestinal, 
cardiovascular, and/or renal AEs. A total of 719 abstracts were reviewed and 385 
were identified as relevant studies for full screening; 16 studies were included. 
RESULTS: Risk of gastrointestinal events was greatest in current users of NSAIDs 
and generally occurred within the first 30 days of treatment. Risk remained 
constant over the first year and quickly returned to baseline after NSAIDs were 
discontinued, generally within 2 months. Risk of a cardiovascular event, 
including first myocardial infarction, was more evident early in treatment (as 
early as 7 days; median, 9 days) and remained elevated for up to 1 week after the 
last prescription. In patients with a prior history of myocardial infarction, even 
short-term use was associated with increased risk. Acute renal failure was the 
most common form of NSAID-induced renal impairment, with rapid onset 
following administration of first dose, but was often reversible upon 
discontinuation of NSAIDs CONCLUSIONS: The risk of gastrointestinal, 
cardiovascular, and renal NSAID-induced events can occur within the first 7 days 
after initiation of therapy. These events generally occur earlier than previously 
recognized, with the highest risk of an event occurring within the first few 
weeks. This trend either remains constant or decreases over time with long-term 
NSAID use.  
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OBJECTIVES: In this study, we quantify common complications that happen 
within 30 days of bariatric surgery, determine if risk of complication depends on 
the type of bariatric procedure, and identify risk factors for each procedure type. 
METHODS: Medical claims data were used to obtain information on 5,527 
patients in the southeastern PA region who had one of three bariatric procedures 
between January 2009 and May 2012. Relevant pre-existing medical conditions 
and common complications within 30 days of surgery were identified by 
diagnosis and procedure codes from claims. Logistic regression models were 
used to determine significant predictors of having a complication, controlling for 
factors such as age, gender, illness burden, and facility effects. RESULTS: There 
were 5,527 surgeries, of which 60% were gastric bypass, 29% were adjustable 
band, and 11% were gastric sleeve procedures. The most common complications 
within 30 days of surgery were nausea and vomiting, anastomatic leakage, 
intestinal obstruction, dehydration, and vitamin deficiency. After controlling for 
factors such as age, gender, illness burden, and facility, patients undergoing 
gastric bypass or gastric sleeve had significantly greater odds of developing 
complications than patients who had the adjustable band. The strongest 
predictors for complications for gastric bypass were a history of COPD, 
hypertension, or deep venous thrombosis/pulmonary embolism. For gastric 
sleeve, depression was a significant risk factor, and for the adjustable band, a 
history of COPD, deep venous thrombosis/pulmonary embolism, or type II 
diabetes were significant risk factors. CONCLUSIONS: The type of procedure 
(gastric bypass, gastric sleeve, or adjustable band) plays a significant role in the 
risk for complications within 30 days of bariatric surgery, with gastric bypass and 
gastric sleeve procedures having greater odds of complication than the 
adjustable band procedure. Certain pre-existing conditions such as COPD and 
deep venous thrombosis/pulmonary embolism also increase the odds for 
complications.  
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OBJECTIVES: To assess the clinical and economic burden of obesity in the  
U.S. veteran population. METHODS: This analysis was conducted on a study 
sample from the Veterans Health Administration (VHA) Medical SAS datasets 
from 2005 through 2012. All patients diagnosed with obesity during the study 
period were identified using International Classification of Disease 9thRevision 
Clinical Modification (ICD-9-CM) diagnosis code 278.x. Patient body mass index 
(BMI), clinical status and economic burden were examined. Descriptive statistics 
were calculated as means ± standard deviation (SD) and percentages to measure 
the cost, and utilization distribution in the sample. RESULTS: A total of 1,082,170 
veteran patients were diagnosed with obesity in the study period. The average 
BMI of these patients was 36.27. Among these patients, 48.58% had a BMI of ≥35, 
and 36.40% had a BMI between 30 and 35. The total number of patients with a 
BMI of <25 was only 0.3%. Unspecified essential hypertension (26.61%), type  
2 diabetes mellitus (19.02%) and unspecified hyperlipidemia (9.36%) were the 
most commonly diagnosed comorbid conditions. Almost all patients had follow-
up outpatient visits (99.97%), and only 10.58% of patients experienced  
an inpatient admission. Average inpatient costs for these patients were $3164; 
outpatient costs were $6700; office visit costs $6277; pharmacy costs $1296; and 
emergency room (ER) costs $192. CONCLUSIONS: Hypertension, diabetes  
and hyperlipidemia may be related to obesity. Comorbid conditions should  
be assessed and treated to improve the overall burden of illness in obese 
patients.  
